NASDAQ$AHCO

AdaptHealth Corp. · Q2 2022 earnings

Q2 2022 earnings · · Investor relations

Briefing

Announced financial results for the second quarter ended June 30, 2022.

AdaptHealth reported its Q2 2022 results, highlighting resilience in HME and Sleep product lines with CPAP patient setups near record levels and a 16% increase in rental census from February levels. The diabetes product line also posted double-digit growth. The company maintains its fiscal year 2022 guidance.

  • Cash flow from operations was $103.5 million, compared to $129.2 million in the second quarter of 2021.
  • HME and Sleep product lines showed continued resilience.
  • CPAP patient set ups remain at or near record levels resulting in rental census up 16% from February levels.
  • Diabetes product line continues to post double-digit growth.

Headline financials

Total Revenue

$728M

Previous: $617M+17.9%
EPS (adj)

$0.09

Previous: $0.17-47.1%
Capital Expenditures

-$154M

Previous: -$79.4M-94.4%
Free Cash Flow

-$140M

Previous: -$289K-48449.5%
Net Income

$14M

Previous: $79.1M-82.3%
Operating Income

$59.2M

Previous: $65.4M-9.5%
Gross Profit

$118M

Previous: $126M-6.9%
Cash & Equivalents

$55.8M

Previous: $178M-68.7%
Total Assets

$5.2B

Previous: $4.69B+11.0%
Stock-Based Comp

$5.72M

Previous: $7.45M-23.2%

Revenue & EPS history

AdaptHealth · Revenue · Quarterly

$728M

Q2 2022+17.9%vs Q2 2021
Beat estimate in 7 of 15 quarters(47%)
ActualEstimate

Forward guidance

The Company is maintaining its previously issued financial guidance for fiscal year 2022. Guidance for fiscal year 2022 does not include any contribution from acquisitions that have not yet closed, or continuing Public Health Emergency benefits beyond the currently scheduled expiration date.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q2 2022

Historical avgQ2 2022

+0.6%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.6%

Avg return

30 days after

52%

16 / 31 earnings

Positive

+34.6%

Q4 2023

Best reaction

-27.9%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-10.0%-13.4%-25.6%
Q4 2025-14.2%-11.1%+10.9%
Q3 2025+17.2%+4.5%+3.2%
Q1 2025+1.7%-1.4%+3.7%
Q4 2024+24.4%+33.1%+24.4%
Q3 2024+0.3%-0.6%-4.2%
Q2 2024-17.2%-14.1%+4.6%
Q1 2024-8.6%-8.8%+4.9%
Q4 2023+34.6%+37.9%+50.9%
Q3 2023-23.1%-18.6%-5.6%
Q2 2023+11.1%+4.4%-19.8%
Q1 2023-8.4%-12.2%-13.8%
Q4 2022-27.9%-27.9%-40.6%
Q3 2022-1.6%+8.4%+4.5%
Q2 2022-8.9%-8.2%-25.7%
Q1 2022+23.7%+42.2%+53.6%
Q4 2021+4.1%+2.3%+2.8%
Q3 2021-5.4%-7.2%-24.1%
Q2 2021+16.4%+13.4%+12.3%
Q1 2021-8.5%-14.9%-10.4%
Q4 2020+2.1%+12.4%+21.7%
Q3 2020+2.6%+0.6%+19.5%
Q2 2020+13.9%+18.0%+7.0%
Q1 2020+1.6%+5.8%+5.5%
Q4 2019+1.8%+1.4%-7.7%
Q3 2019-4.1%-4.9%-3.3%
Q2 2019+0.0%+0.0%-0.6%
Q1 2019+0.0%+0.0%+0.3%
Q4 2018+0.6%+0.7%+1.3%
Q3 2018+0.3%+0.1%+0.4%
Q2 2018+0.0%+0.3%+0.1%
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro